We are live on
!
Find out more
O
OrbiMed Portfolio holdings
AUM
$5.05B
1-Year Est. Return
125.28%
This Fund
S&P 500
This Quarter
Est. Return
+8.13%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$4.72B
AUM Growth
–
Cap. Flow
+$4.69B
Cap. Flow
% of AUM
99.51%
Top 10 Holdings %
Top 10 Hldgs %
37.69%
Holding
127
New
123
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amgen
AMGN
|
+$272M |
| 2 |
Gilead Sciences
GILD
|
+$251M |
| 3 |
Biogen
BIIB
|
+$219M |
| 4 |
Merck
MRK
|
+$193M |
| 5 |
Viatris
VTRS
|
+$149M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 80.02% |
| 2 | Financials | 2.05% |
| 3 | Technology | 0.14% |
| 4 | Utilities | 0.01% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Medtronic
MDT
$112B
| $9.9M | 0.21% |
+192,300
| New | +$9.51M |
|
|
DVAX
77
DELISTED
Dynavax Technologies
DVAX
| $9.88M | 0.21% |
+898,600
| New | +$18.9M |
|
|
XOMA
78
DELISTED
Xoma
XOMA
| $9.39M | 0.2% |
+129,296
| New | +$9.62M |
|
|
79
CALL
Viatris
VTRS
$20.9B
| $9.31M | 0.2% |
+300,000
| New | +$8.96M |
|
80
Cardinal Health
CAH
$54.3B
| $8.94M | 0.19% |
+189,300
| New | +$8.65M |
|
81
McKesson
MCK
$105B
| $8.7M | 0.18% |
+76,000
| New | +$8.46M |
|
|
ECYT
82
DELISTED
Endocyte, Inc. Common Stock
ECYT
| $8.69M | 0.18% |
+662,000
| New | +$8.93M |
|
|
PTX
83
DELISTED
Pernix Therapeutics Holdings, Inc.
PTX
| $8.38M | 0.18% |
+232,080
| New | +$8.7M |
|
84
DaVita
DVA
$15.6B
| $7.85M | 0.17% |
+130,000
| New | +$8.12M |
|
|
OPTR
85
DELISTED
OPTIMER PHARMACEUTICALS, INC. COM STK
OPTR
| $7.76M | 0.16% |
+536,000
| New | +$7.81M |
|
86
InspireMD
NSPR
$30.9M
| $7.5M | 0.16% |
+1
| New | +$15.6M |
|
87
Stryker
SYK
$134B
| $7.42M | 0.16% |
+114,800
| New | +$7.62M |
|
|
SVA
88
DELISTED
Sinovac Biotech, Ltd
SVA
| $7.41M | 0.16% |
+1,884,200
| New | +$7.01M |
|
|
ELN
89
CALL
DELISTED
ELAN CORP ADS(RP1 ORD4IRISH PN
ELN
| $7.07M | 0.15% |
+500,000
| New | +$6.18M |
|
|
STJ
90
DELISTED
St Jude Medical
STJ
| $6.62M | 0.14% |
+145,000
| New | +$6.28M |
|
|
VCRA
91
DELISTED
VOCERA COMMUNICATIONS, INC.
VCRA
| $6.58M | 0.14% |
+447,500
| New | +$7.65M |
|
|
ARQL
92
DELISTED
Arqule Inc
ARQL
| $6.5M | 0.14% |
+2,804,000
| New | +$7.56M |
|
|
SGEN
93
CALL
DELISTED
Seagen Inc. Common Stock
SGEN
| $6.29M | 0.13% |
+200,000
| New | +$6.98M |
|
94
Curis
CRIS
$9.59M
| $6.22M | 0.13% |
+975
| New | +$6.89M |
|
95
Zimmer Biomet
ZBH
$18.7B
| $6.09M | 0.13% |
+83,739
| New | +$6.26M |
|
96
Bio-Techne
TECH
$11.2B
| $5.94M | 0.13% |
+344,000
| New | +$5.71M |
|
|
CFN
97
DELISTED
CAREFUSION CORPORATION
CFN
| $5.71M | 0.12% |
+154,900
| New | +$5.48M |
|
98
Jazz Pharmaceuticals
JAZZ
$16.2B
| $4.95M | 0.1% |
+72,000
| New | +$4.4M |
|
|
FRX
99
DELISTED
FOREST LABORATORIES INC
FRX
| $4.92M | 0.1% |
+120,000
| New | +$4.64M |
|
100
CALL
Eli Lilly
LLY
$1.09T
| $4.91M | 0.1% |
+100,000
| New | +$5.44M |
|
Similar funds
HSA
LIM
NL
BPWM
LFG
JIM
CTC
PAMP
OrbiMed's Q2 2013 Portfolio in Review
Q2 2013 is the first quarter with a 13F filing on record for OrbiMed, which disclosed 127 positions worth $4.72B. Its ten largest holdings account for 38% of the portfolio.
Its largest position is Amgen: 2,619,400 shares worth $258M.
By sector, the portfolio is most concentrated in Healthcare at 80% of assets, followed by Financials and Technology.
- OrbiMed's largest Q2 2013 buy was Amgen: 2,619,400 shares worth $258M.
- OrbiMed's ten largest holdings make up 38% of its $4.72B portfolio in Q2 2013.
- OrbiMed disclosed 127 positions in Q2 2013, its first 13F filing on record.
Based on OrbiMed's 13F filing for Q2 2013, filed 14 Aug 2013.